Bluejay Diagnostics Inc.
BJDX | NASDAQ
$1
+$0.09 (+9.65%)
At close: Sep 22, 2026, 4:00 PM ET
$1.04
+$0.04 (+4.00%)
After-hours:
Sep 22, 2026, 7:59 PM ET
Company Profile
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Indranil Dey | Principal Financial, Accounting & Executive Officer, President, Chief Executive Officer and Director |
| Kevin Vance | Chief Commercial Officer |
| Mark W. Feinberg | Chief Medical Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 13, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 13, 2026 | 8-K | Current Report |
| Aug 12, 2026 | S-8 | Filing |
| Aug 12, 2026 | 10-Q | Quarterly Report |
Bluejay Diagnostics Inc.
| Country | United States |
| IPO Date | Nov 9, 2021 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Indranil Dey |
Contact Details
360 Massachusetts Avenue Acton,
Massachusetts 01720 United States
Stock Details
| Ticker Symbol | BJDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001704287 |
| CUSIP Number | 095633608 |
| ISIN Number | US0956336087 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove BJDX